Ascrinvacumab is under clinical development by Kintor Pharmaceutical and currently in Phase I for Liver Cancer. According to GlobalData, Phase I drugs for Liver Cancer have a 78% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Ascrinvacumab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Ascrinvacumab overview
Ascrinvacumab (PF-03446962) is under development for the treatment of advanced solid tumors including metastatic hepatocellular carcinoma, solid tumor and liver cancer. It is also under development for the treatment of ESCC, urothelial cancer, HCC, gastroesophageal junction adenocarcinoma and gastric cancer in combination with KN046. The drug candidate is administered intravenously. It is a fully-human monoclonal antibody (IgG2) against ALK-1.
The drug candidate was also under development for malignant pleural mesothelioma, refractory metastatic colorectal cancer, relapsed or refractory urothelial cancer, breast cancer, prostate cancer, and age related macular degeneration.
Kintor Pharmaceutical overview
Kintor Pharmaceutical (Kintor) is a clinical stage drug company. The company’s pipeline products include KX-826 and AR-PROTAC (GT20029) is for the treatment of androgenetic alopecia (male), androgenetic alopecia (female), androgenetic alopecia (male), androgenetic alopecia (long-term safety), combined with minoxidil for androgenetic alopecia (male), acne vulgaris, acne vulgaris; pruxelutamide (GT0918) treats COVID-19; GT1708F1 targets idiopathic pulmonary fibrosis (IPF) and blood cancer; GT0486 for metastatic solid tumors; ALK-1 (GT90001) is for the treatment of combination therapy with a PD-1 for metastatic hepatocellular carcinoma (HCC), angiogenesis inhibitor combination therapy with a PD-1 for metastatic hepatocellular carcinoma (HCC), combination therapy with a PD-1 for metastatic hepatocellular carcinoma (HCC). The company operates in Hong Kong, China, and the US. Kintor is headquartered in Suzhou, Jiangsu, China.
For a complete picture of Ascrinvacumab’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
